Two Phase II studies, one in renal cell carcinoma [NCT01391130] and one in small cell lung cancer [NCT 01439568] have evaluated the efficacy of the CXCR4 peptidic inhibitor LY2410924® (Eli Lilly and Company) in combination with sunitinib and carboplatin/etoposide respectively. This evidence concerns the gene CXCR4 and small cell lung carcinoma.